A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Mesothelioma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate743
- Sponsors Bristol-Myers Squibb
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 14 Nov 2016 Planned End Date changed from 1 Aug 2021 to 1 Sep 2021.
- 14 Nov 2016 Status changed from not yet recruiting to recruiting.